Overall, these results support that KU757 overcomes some of the pathways driving BRAF and MEK inhibitor resistance by downregulating key tumour‐promoting genes and upregulating tumour suppressors, several of which are drivers of MAPK resistance. Here, BRAF is linked to neoplasm.